Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | AXL | P30530 | 3/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.44 |
| ▸ | MERTK | Q12866 | 6/20 | 0.44 |
| ▸ | FLT3 | P36888 | 5/20 | 0.44 |
| ▸ | GAS6 | Q14393 | 5/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763976 | 0.94 | MAPK8 (0.44) | KMT2AAXLTYRO3MERTKFLT3 | |
| SCHEMBL20299364 | 0.82 | KMT2A (0.61) | KMT2AAXLTYRO3MERTKFLT3 | |
| SCHEMBL31324932 | 0.82 | KMT2A (0.57) | KMT2AAXLTYRO3MERTKFLT3 | |
| SCHEMBL31360739 | 0.82 | KMT2A (0.57) | KMT2AAXLTYRO3MERTKFLT3 | |
| SCHEMBL29526968 | 0.81 | MAPK8 (0.61) | KMT2AMAPK8SYK | |
| SCHEMBL13518145 | 0.80 | KMT2A (0.58) | KMT2AAXLTYRO3MERTKFLT3 | |
| SCHEMBL28533353 | 0.80 | KMT2A (0.55) | KMT2AAXLMERTKMAPK8MAPK9 | |
| SCHEMBL20609719 | 0.80 | TYRO3 (0.64) | KMT2AAXLTYRO3MERTKFLT3 | |
| SCHEMBL13518131 | 0.79 | KMT2A (0.61) | KMT2AAXLTYRO3MERTKFLT3 | |
| Fluoride SCHEMBL13518132 | 0.79 | KMT2A (0.57) | KMT2AAXLTYRO3MERTKFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007071455-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1794134-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES AS CELL CYCLE KINASE INHIBITORS OR RECEPTOR TYROSINE KINASE INHIBITORS, PRODUCTION OF SAID SUBSTANCES AND USE OF THE LATTER AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-20060111378-A1 | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-25 | — | — | US | disclosed |
| WO-2006034872-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES AS CELL CYCLE KINASE INHIBITORS OR RECEPTOR TYROSINE KINASE INHIBITORS, PRODUCTION OF SAID SUBSTANCES AND USE OF THE LATTER AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | WO | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111378-A1 | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | CDK2, KDR, CDK4 | KMT2A 1366/4885AXL 143/4885TYRO3 135/4885 |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | TYMS, DPYD, DHFR | KMT2A 4091/4885AXL 326/4885TYRO3 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.